149 related articles for article (PubMed ID: 8002858)
1. The role of high dose 67-gallium scintigraphy in staging untreated patients with lymphoma.
Larcos G; Farlow DC; Antico VF; Gruenewald SM; Boyages J
Aust N Z J Med; 1994 Feb; 24(1):5-8. PubMed ID: 8002858
[TBL] [Abstract][Full Text] [Related]
2. Gallium-67 scintigraphy in lymphoma: is there a benefit of image fusion with computed tomography?
Chajari M; Lacroix J; Peny AM; Chesnay E; Batalla A; Henry-Amar M; Delcambre C; Génot JY; Fruchard C; Bardet S
Eur J Nucl Med Mol Imaging; 2002 Mar; 29(3):380-7. PubMed ID: 12002715
[TBL] [Abstract][Full Text] [Related]
3. Clinical relevance of gallium-67 scintigraphy in lymphoma before and after therapy.
Delcambre C; Reman O; Henry-Amar M; Peny AM; Macro M; Cheze S; Génot JY; Tanguy A; Switsers O; Van HL; Couëtte JE; Leporrier M; Bardet S
Eur J Nucl Med; 2000 Feb; 27(2):176-84. PubMed ID: 10755723
[TBL] [Abstract][Full Text] [Related]
4. Monitoring bulky mediastinal disease with gallium-67, CT-scan and magnetic resonance imaging in Hodgkin's disease and high-grade non-Hodgkin's lymphoma.
Zinzani PL; Zompatori M; Bendandi M; Battista G; Fanti S; Barbieri E; Gherlinzoni F; Rimondi MR; Frezza G; Pisi P; Merla E; Gozzetti A; Canini R; Monetti N; Babini L; Tura S
Leuk Lymphoma; 1996 Jun; 22(1-2):131-5. PubMed ID: 8724540
[TBL] [Abstract][Full Text] [Related]
5. [SPECT-CT 67Ga studies in lymphoma disease. Contribution to staging and follow-up].
Fuertes Manuel J; Estorch Cabrera M; Camacho Martí V; Flotats Giralt A; Rodríguez-Revuelto AA; Hernández Fructuoso MA; Carrió Gasset I
Rev Esp Med Nucl; 2006; 25(4):242-9. PubMed ID: 16827987
[TBL] [Abstract][Full Text] [Related]
6. Comparison of bone and 67Ga scintigraphy in the initial diagnosis of bone involvement in children with malignant lymphoma.
Mouratidis B; Gilday DL; Ash JM
Nucl Med Commun; 1994 Mar; 15(3):144-7. PubMed ID: 8190402
[TBL] [Abstract][Full Text] [Related]
7. Comparison of gallium-67-citrate and thallium-201 scintigraphy in peripheral and intrathoracic lymphoma.
Waxman AD; Eller D; Ashook G; Ramanna L; Brachman M; Heifetz L; McAndrews P; Bierman H; Taub R; Avedo M; Wall F
J Nucl Med; 1996 Jan; 37(1):46-50. PubMed ID: 8544000
[TBL] [Abstract][Full Text] [Related]
8. Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma.
Sasaki M; Kuwabara Y; Koga H; Nakagawa M; Chen T; Kaneko K; Hayashi K; Nakamura K; Masuda K
Ann Nucl Med; 2002 Jul; 16(5):337-45. PubMed ID: 12230093
[TBL] [Abstract][Full Text] [Related]
9. Bone lymphoma: 67Ga scintigraphy and CT for prediction of outcome after treatment.
Israel O; Mekel M; Bar-Shalom R; Epelbaum R; Hermony N; Haim N; Dann EJ; Frenkel A; Ben-Arush M; Gaitini D
J Nucl Med; 2002 Oct; 43(10):1295-303. PubMed ID: 12368366
[TBL] [Abstract][Full Text] [Related]
10. 18FDG PET versus high-dose 67Ga scintigraphy for restaging and treatment follow-up of lymphoma patients.
Van Den Bossche B; Lambert B; De Winter F; Kolindou A; Dierckx RA; Noens L; Van De Wiele C
Nucl Med Commun; 2002 Nov; 23(11):1079-83. PubMed ID: 12411836
[TBL] [Abstract][Full Text] [Related]
11. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma.
Wirth A; Seymour JF; Hicks RJ; Ware R; Fisher R; Prince M; MacManus MP; Ryan G; Januszewicz H; Wolf M
Am J Med; 2002 Mar; 112(4):262-8. PubMed ID: 11893364
[TBL] [Abstract][Full Text] [Related]
12. Three cases demonstrating the role of gallium scanning in relapsing Hodgkin's disease and non-Hodgkin lymphoma.
Zollars LE; Nagel JS; Tumeh SS
J Nucl Med; 1987 Oct; 28(10):1611-5. PubMed ID: 3655913
[TBL] [Abstract][Full Text] [Related]
13. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma.
Shen YY; Kao A; Yen RF
Oncol Rep; 2002; 9(2):321-5. PubMed ID: 11836600
[TBL] [Abstract][Full Text] [Related]
14. [False-positive findings of 67-gallium scintigraphy in staging/restaging of malignant lymphoma].
Bihl H; Kimmig B
Rofo; 1987 Feb; 146(2):172-7. PubMed ID: 3029830
[TBL] [Abstract][Full Text] [Related]
15. The continuing clinical role of gallium 67 scintigraphy in the age of receptor imaging.
Front D; Bar-Shalom R; Israel O
Semin Nucl Med; 1997 Jan; 27(1):68-74. PubMed ID: 9122725
[TBL] [Abstract][Full Text] [Related]
16. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma.
Hoh CK; Glaspy J; Rosen P; Dahlbom M; Lee SJ; Kunkel L; Hawkin RA; Maddahi J; Phelps ME
J Nucl Med; 1997 Mar; 38(3):343-8. PubMed ID: 9074514
[TBL] [Abstract][Full Text] [Related]
17. 67Ga scintigraphy for the evaluation of recurrences and residual masses in patients with lymphoma.
Setoain FJ; Pons F; Herranz R; Vidal-Sicart S; Lomeña F; Ayuso C; Montserrat E; Setoain J
Nucl Med Commun; 1997 May; 18(5):405-11. PubMed ID: 9194081
[TBL] [Abstract][Full Text] [Related]
18. Thallium-201 scintigraphy in pediatric soft-tissue tumors.
Howman-Giles R; Uren RF; Shaw PJ
J Nucl Med; 1995 Aug; 36(8):1372-6. PubMed ID: 7629580
[TBL] [Abstract][Full Text] [Related]
19. Utility of gallium-67 scintigraphy in low-grade non-Hodgkin's lymphoma.
Ben-Haim S; Bar-Shalom R; Israel O; Haim N; Epelbaum R; Ben-Shachar M; Gaitini D; Kolodny GM; Front D
J Clin Oncol; 1996 Jun; 14(6):1936-42. PubMed ID: 8656263
[TBL] [Abstract][Full Text] [Related]
20. 18F-FDG PET is superior to 67Ga SPECT in the staging of non-Hodgkin's lymphoma.
Yamamoto F; Tsukamoto E; Nakada K; Takei T; Zhao S; Asaka M; Tamaki N
Ann Nucl Med; 2004 Sep; 18(6):519-26. PubMed ID: 15515753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
